What is The Beauty Health Company's earnings per share (EPS)?

The Beauty Health Company (SKIN) reported diluted earnings per share of $-0.16 for fiscal year 2025. This represents a 55.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

The Beauty Health Company Financials

SKIN

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows The Beauty Health Company (SKIN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 18/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

The Beauty Health Company has an operating margin of -6.9%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 7/100, suggesting thin profitability after operating expenses. This is up from -20.3% the prior year.

Growth

The Beauty Health Company's revenue declined 10% year-over-year, from $334.3M to $300.8M. This contraction results in a growth score of 17/100.

Leverage

The Beauty Health Company has elevated debt relative to equity (D/E of 7.19), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

The Beauty Health Company's current ratio of 1.66 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 29/100, which could limit financial flexibility.

Cash Flow

The Beauty Health Company has a free cash flow margin of 12.4%, earning a moderate score of 56/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

The Beauty Health Company generates a -15.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -56.2% the prior year.

Piotroski F-Score Neutral

6/9

The Beauty Health Company passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-3.94x

For every $1 of reported earnings, The Beauty Health Company generates $-3.94 in operating cash flow ($37.5M OCF vs -$9.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-1.1x

The Beauty Health Company earns $-1.1 in operating income for every $1 of interest expense (-$20.8M vs $19.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$300.8M

YoY-10.0%

5Y CAGR+20.4%

The Beauty Health Company generated $300.8M in revenue in fiscal year 2025. This represents a decrease of 10.0% from the prior year.

EBITDA

$33K

YoY+100.1%

The Beauty Health Company's EBITDA was $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.

Net Income

-$9.5M

YoY+67.3%

The Beauty Health Company reported -$9.5M in net income in fiscal year 2025. This represents an increase of 67.3% from the prior year.

EPS (Diluted)

$-0.16

YoY+55.6%

The Beauty Health Company earned $-0.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 55.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$37.2M

YoY+141.8%

The Beauty Health Company generated $37.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 141.8% from the prior year.

Cash & Debt

$232.7M

YoY-37.1%

5Y CAGR+89.6%

The Beauty Health Company held $232.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

128M

YoY+2.1%

The Beauty Health Company had 128M shares outstanding in fiscal year 2025. This represents an increase of 2.1% from the prior year.

Margins & Returns

Gross Margin

65.3%

YoY+10.8pp

5Y CAGR+8.9pp

The Beauty Health Company's gross margin was 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.8 percentage points from the prior year.

Operating Margin

-6.9%

YoY+13.4pp

5Y CAGR+7.5pp

The Beauty Health Company's operating margin was -6.9% in fiscal year 2025, reflecting core business profitability. This is up 13.4 percentage points from the prior year.

Net Margin

-3.2%

YoY+5.5pp

5Y CAGR+21.3pp

The Beauty Health Company's net profit margin was -3.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5.5 percentage points from the prior year.

Return on Equity

-15.6%

YoY+40.6pp

The Beauty Health Company's ROE was -15.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 40.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.6M

YoY-10.6%

5Y CAGR+10.5%

The Beauty Health Company invested $5.6M in research and development in fiscal year 2025. This represents a decrease of 10.6% from the prior year.

Share Buybacks

The Beauty Health Company spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$303K

YoY-59.9%

5Y CAGR-38.7%

The Beauty Health Company invested $303K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.9% from the prior year.

SKIN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$300.8M-10.0%	$334.3M-16.0%	$398.0M+8.8%	$365.9M+40.7%	$260.1M+118.4%	$119.1M
Cost of Revenue	$104.4M-31.3%	$152.0M-37.4%	$242.9M+107.4%	$117.1M+43.6%	$81.5M+57.1%	$51.9M
Gross Profit	$196.4M+7.7%	$182.3M+17.5%	$155.1M-37.7%	$248.8M+39.3%	$178.5M+165.7%	$67.2M
R&D Expenses	$5.6M-10.6%	$6.3M-37.7%	$10.1M+19.6%	$8.4M+3.0%	$8.2M+140.4%	$3.4M
SG&A Expenses	$117.9M-6.0%	$125.5M-4.5%	$131.4M+23.9%	$106.1M+7.5%	$98.7M+222.0%	$30.6M
Operating Income	-$20.8M+69.3%	-$67.8M+48.2%	-$130.9M-406.6%	-$25.8M+35.3%	-$39.9M-132.4%	-$17.2M
Interest Expense	$19.3M+85.6%	$10.4M-23.7%	$13.6M+1.9%	$13.4M+13.7%	$11.8M	N/A
Income Tax	$3.6M+892.3%	-$452K+74.5%	-$1.8M-259.0%	$1.1M+159.5%	-$1.9M+79.9%	-$9.3M
Net Income	-$9.5M+67.3%	-$29.1M+70.9%	-$100.1M-326.4%	$44.2M+111.7%	-$378.8M-1198.2%	-$29.2M
EPS (Diluted)	$-0.16+55.6%	$-0.36+52.6%	$-0.76-230.4%	$-0.23+93.8%	$-3.71	$-0.85

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$82.4M+16.6%	$70.7M-9.6%	$78.2M+12.4%	$69.6M-16.7%	$83.5M+6.0%	$78.8M-13.0%	$90.6M+11.3%	$81.4M
Cost of Revenue	$29.3M+17.2%	$25.0M-13.9%	$29.1M+38.5%	$21.0M-32.6%	$31.1M-18.4%	$38.2M-23.2%	$49.7M+50.3%	$33.0M
Gross Profit	$53.0M+16.2%	$45.6M-7.1%	$49.1M+1.1%	$48.6M-7.2%	$52.3M+28.8%	$40.6M-0.7%	$40.9M-15.3%	$48.4M
R&D Expenses	$1.7M-1.0%	$1.7M+35.7%	$1.3M+25.4%	$998K-18.3%	$1.2M+10.3%	$1.1M-4.4%	$1.2M-58.7%	$2.8M
SG&A Expenses	$27.7M-5.4%	$29.3M+6.5%	$27.5M-18.2%	$33.6M+5.7%	$31.8M-5.0%	$33.4M+6.5%	$31.4M+8.8%	$28.9M
Operating Income	$162K+102.6%	-$6.2M-131.2%	-$2.7M+77.5%	-$12.0M-68.0%	-$7.2M+66.7%	-$21.5M+2.7%	-$22.1M-30.1%	-$17.0M
Interest Expense	$6.4M+1.0%	$6.3M+52.3%	$4.1M+65.9%	$2.5M+1.4%	$2.5M-0.2%	$2.5M+0.7%	$2.5M-19.0%	$3.0M
Income Tax	$3.3M+753.9%	$386K+138.9%	-$993K-211.3%	$892K+164.3%	-$1.4M-171.3%	$1.9M+651.8%	-$353K+46.4%	-$659K
Net Income	-$8.1M+26.5%	-$11.0M-156.0%	$19.7M+295.2%	-$10.1M+2.3%	-$10.3M+43.5%	-$18.3M-9155.0%	$202K+129.7%	-$679K
EPS (Diluted)	N/A	$-0.09-400.0%	$0.03+137.5%	$-0.08	N/A	$-0.15-50.0%	$-0.100.0%	$-0.10

SKIN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$499.8M-27.1%	$685.7M-26.2%	$929.1M-7.4%	$1.0B-17.7%	$1.2B+447.0%	$222.8M
Current Assets	$309.5M-35.1%	$477.1M-31.7%	$698.3M-10.9%	$783.3M-21.7%	$1.0B+1593.7%	$59.1M
Cash & Equivalents	$232.7M-37.1%	$370.1M-29.2%	$523.0M-8.0%	$568.2M-37.0%	$901.9M+9407.5%	$9.5M
Inventory	$48.0M-30.5%	$69.1M-24.3%	$91.3M-16.7%	$109.7M+211.0%	$35.3M+52.0%	$23.2M
Accounts Receivable	$21.7M-21.4%	$27.6M-49.5%	$54.7M-28.5%	$76.5M+63.4%	$46.8M+152.1%	$18.6M
Goodwill	$126.6M+2.5%	$123.5M-1.8%	$125.8M+1.0%	$124.6M+0.7%	$123.7M+25.5%	$98.5M
Total Liabilities	$438.7M-30.8%	$633.9M-27.1%	$869.7M+4.0%	$836.0M-8.8%	$916.5M+262.6%	$252.8M
Current Liabilities	$186.3M+173.3%	$68.2M-40.7%	$115.0M+60.4%	$71.7M-6.2%	$76.4M+147.1%	$30.9M
Long-Term Debt	N/A	$552.2M	N/A	N/A	N/A	N/A
Total Equity	$61.1M+17.9%	$51.8M-12.8%	$59.4M-64.4%	$167.1M-43.9%	$298.0M+1075.0%	-$30.6M
Retained Earnings	-$517.5M-1.9%	-$508.0M-6.1%	-$478.9M-26.4%	-$378.8M+9.5%	-$418.7M-860.3%	-$43.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$499.8M-0.8%	$503.6M-0.8%	$507.6M-24.7%	$673.8M-1.7%	$685.7M-2.0%	$699.5M-1.7%	$711.8M-15.7%	$844.7M
Current Assets	$309.5M+0.4%	$308.4M+0.7%	$306.1M-34.8%	$469.4M-1.6%	$477.1M-1.6%	$485.0M-0.9%	$489.6M-20.4%	$614.8M
Cash & Equivalents	$232.7M+6.1%	$219.4M+3.5%	$212.0M-43.2%	$373.0M+0.8%	$370.1M+3.1%	$358.9M+2.7%	$349.5M-21.4%	$444.6M
Inventory	$48.0M-14.5%	$56.1M-5.1%	$59.2M-9.8%	$65.6M-5.0%	$69.1M-5.9%	$73.4M-4.8%	$77.1M-19.4%	$95.7M
Accounts Receivable	$21.7M-2.1%	$22.2M-11.3%	$25.0M+7.7%	$23.3M-15.9%	$27.6M-23.8%	$36.3M-12.4%	$41.4M-13.1%	$47.7M
Goodwill	$126.6M+0.1%	$126.5M+0.2%	$126.3M+1.6%	$124.3M+0.6%	$123.5M-1.6%	$125.5M+0.5%	$124.8M-0.4%	$125.4M
Total Liabilities	$438.7M+0.2%	$438.0M+1.0%	$433.6M-30.9%	$627.8M-1.0%	$633.9M-0.9%	$639.8M-0.4%	$642.6M-17.8%	$781.4M
Current Liabilities	$186.3M+200.9%	$61.9M+4.1%	$59.4M-5.4%	$62.8M-7.8%	$68.2M-7.8%	$73.9M-2.0%	$75.4M-19.4%	$93.6M
Long-Term Debt	N/A	$363.4M+0.1%	$363.1M	N/A	$552.2M	N/A	N/A	N/A
Total Equity	$61.1M-7.0%	$65.7M-11.3%	$74.0M+60.7%	$46.1M-11.1%	$51.8M-13.3%	$59.7M-13.7%	$69.2M+9.3%	$63.3M
Retained Earnings	-$517.5M-1.6%	-$509.4M-2.2%	-$498.3M+3.8%	-$518.1M-2.0%	-$508.0M-2.1%	-$497.6M-3.8%	-$479.3M0.0%	-$479.5M

SKIN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$37.5M+132.3%	$16.1M-25.8%	$21.8M+120.4%	-$106.6M-275.9%	-$28.4M-128.1%	-$12.4M
Capital Expenditures	$303K-59.9%	$756K-80.2%	$3.8M-64.7%	$10.8M-3.2%	$11.2M+219.9%	$3.5M
Free Cash Flow	$37.2M+141.8%	$15.4M-14.2%	$17.9M+115.3%	-$117.4M-196.9%	-$39.6M-148.2%	-$15.9M
Investing Cash Flow	-$5.2M+24.0%	-$6.8M+78.4%	-$31.5M-67.0%	-$18.9M+50.0%	-$37.7M-888.5%	-$3.8M
Financing Cash Flow	-$174.9M-10.5%	-$158.3M-322.8%	-$37.4M+81.8%	-$205.2M-121.4%	$959.0M+5148.4%	$18.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$30.2M-81.2%	$160.0M	$0-100.0%	$154K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$15.2M+57.5%	$9.6M0.0%	$9.6M+222.0%	$3.0M-81.8%	$16.5M+59.7%	$10.3M+66.3%	$6.2M+136.8%	-$16.9M
Capital Expenditures	$139K+414.8%	$27K-70.7%	$92K+104.4%	$45K-39.2%	$74K+1750.0%	$4K-98.8%	$334K-2.9%	$344K
Free Cash Flow	$15.1M+56.5%	$9.6M+0.7%	$9.6M+223.8%	$3.0M-82.0%	$16.4M+59.0%	$10.3M+75.7%	$5.9M+134.1%	-$17.2M
Investing Cash Flow	-$1.4M-27.5%	-$1.1M+30.2%	-$1.6M-35.5%	-$1.1M-32.8%	-$862K+58.8%	-$2.1M-2.6%	-$2.0M-13.1%	-$1.8M
Financing Cash Flow	-$512K+36.2%	-$803K+99.5%	-$173.4M-69244.4%	-$250K+67.5%	-$770K-277.5%	-$204K+99.8%	-$98.7M-68.5%	-$58.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SKIN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	65.3%+10.8pp	54.5%+15.6pp	39.0%-29.0pp	68.0%-0.6pp	68.7%+12.2pp	56.4%
Operating Margin	-6.9%+13.4pp	-20.3%+12.6pp	-32.9%-25.8pp	-7.1%+8.3pp	-15.3%-0.9pp	-14.4%
Net Margin	-3.2%+5.5pp	-8.7%+16.5pp	-25.2%-37.3pp	12.1%+157.7pp	-145.6%-121.1pp	-24.5%
Return on Equity	-15.6%+40.6pp	-56.2%+112.4pp	-168.6%-195.0pp	26.5%+153.6pp	-127.1%	N/A
Return on Assets	-1.9%+2.3pp	-4.2%+6.5pp	-10.8%-15.2pp	4.4%+35.5pp	-31.1%-18.0pp	-13.1%
Current Ratio	1.66-5.3	7.00+0.9	6.07-4.9	10.92-2.2	13.09+11.2	1.91
Debt-to-Equity	7.19-3.5	10.66-4.0	14.64+9.6	5.00+1.9	3.08+11.3	-8.27
FCF Margin	12.4%+7.8pp	4.6%+0.1pp	4.5%+36.6pp	-32.1%-16.9pp	-15.2%-1.8pp	-13.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	64.4%-0.2pp	64.6%+1.8pp	62.8%-7.0pp	69.8%+7.1pp	62.7%+11.1pp	51.6%+6.4pp	45.2%-14.2pp	59.4%
Operating Margin	0.2%+9.0pp	-8.8%-5.4pp	-3.5%+13.8pp	-17.3%-8.7pp	-8.6%+18.7pp	-27.3%-2.9pp	-24.4%-3.5pp	-20.9%
Net Margin	-9.8%+5.8pp	-15.6%-40.8pp	25.2%+39.7pp	-14.5%-2.1pp	-12.4%+10.8pp	-23.2%-23.4pp	0.2%+1.1pp	-0.8%
Return on Equity	-13.3%+3.5pp	-16.8%-43.4pp	26.6%+48.6pp	-21.9%-2.0pp	-19.9%+10.7pp	-30.6%-30.9pp	0.3%+1.4pp	-1.1%
Return on Assets	-1.6%+0.6pp	-2.2%-6.1pp	3.9%+5.4pp	-1.5%+0.0pp	-1.5%+1.1pp	-2.6%-2.6pp	0.0%+0.1pp	-0.1%
Current Ratio	1.66-3.3	4.98-0.2	5.15-2.3	7.47+0.5	7.00+0.4	6.56+0.1	6.49-0.1	6.57
Debt-to-Equity	7.19+1.7	5.53+0.6	4.91-8.7	13.63+3.0	10.66-0.1	10.71+1.4	9.29-3.1	12.35
FCF Margin	18.3%+4.7pp	13.6%+1.4pp	12.2%+8.0pp	4.2%-15.4pp	19.6%+6.6pp	13.1%+6.6pp	6.5%+27.6pp	-21.1%

Similar Companies

Helen Of Troy Ltd HELE

$334.3M

Honest Company, Inc. HNST

$312.7M

Nu Skin Enter NUS

$354.2M

Yatsen Hldg Ltd YSG

$306.0M

Edgewell Pers Care Co EPC

$995.5M

Frequently Asked Questions

What is The Beauty Health Company's annual revenue?

The Beauty Health Company (SKIN) reported $300.8M in total revenue for fiscal year 2025. This represents a -10.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is The Beauty Health Company's revenue growing?

The Beauty Health Company (SKIN) revenue declined by 10% year-over-year, from $334.3M to $300.8M in fiscal year 2025.

Is The Beauty Health Company profitable?

No, The Beauty Health Company (SKIN) reported a net income of -$9.5M in fiscal year 2025, with a net profit margin of -3.2%.

What is The Beauty Health Company's EBITDA?

The Beauty Health Company (SKIN) had EBITDA of $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is The Beauty Health Company's gross margin?

The Beauty Health Company (SKIN) had a gross margin of 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is The Beauty Health Company's operating margin?

The Beauty Health Company (SKIN) had an operating margin of -6.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is The Beauty Health Company's net profit margin?

The Beauty Health Company (SKIN) had a net profit margin of -3.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is The Beauty Health Company's return on equity (ROE)?

The Beauty Health Company (SKIN) has a return on equity of -15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is The Beauty Health Company's free cash flow?

The Beauty Health Company (SKIN) generated $37.2M in free cash flow during fiscal year 2025. This represents a 141.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is The Beauty Health Company's operating cash flow?

The Beauty Health Company (SKIN) generated $37.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are The Beauty Health Company's total assets?

The Beauty Health Company (SKIN) had $499.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are The Beauty Health Company's capital expenditures?

The Beauty Health Company (SKIN) invested $303K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does The Beauty Health Company spend on research and development?

The Beauty Health Company (SKIN) invested $5.6M in research and development during fiscal year 2025.

How many shares does The Beauty Health Company have outstanding?

The Beauty Health Company (SKIN) had 128M shares outstanding as of fiscal year 2025.

What is The Beauty Health Company's current ratio?

The Beauty Health Company (SKIN) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.

What is The Beauty Health Company's debt-to-equity ratio?

The Beauty Health Company (SKIN) had a debt-to-equity ratio of 7.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is The Beauty Health Company's return on assets (ROA)?

The Beauty Health Company (SKIN) had a return on assets of -1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is The Beauty Health Company's Piotroski F-Score?

The Beauty Health Company (SKIN) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are The Beauty Health Company's earnings high quality?

The Beauty Health Company (SKIN) has an earnings quality ratio of -3.94x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can The Beauty Health Company cover its interest payments?

The Beauty Health Company (SKIN) has an interest coverage ratio of -1.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is The Beauty Health Company?

The Beauty Health Company (SKIN) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.